PACIRA BIOSCIENCES, INC. Proceeds from Sale of Debt Securities, Available-for-sale
PACIRA BIOSCIENCES, INC. (PCRX) reported Proceeds from Sale of Debt Securities, Available-for-sale of $1.07 billion for the 12-month period ending 2021-12-31, per its 10-K filed 2022-02-28.
Discontinued › Cash Flow › Investing Activities
us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt · last filed 2022-02-28
- PACIRA BIOSCIENCES, INC. proceeds from sale of debt securities, available-for-sale for fiscal 2021 was $1.07B, a 247.14% increase from fiscal 2020.
- PACIRA BIOSCIENCES, INC. proceeds from sale of debt securities, available-for-sale for fiscal 2020 was $307.87M, a 3.63% decline from fiscal 2019.
- PACIRA BIOSCIENCES, INC. proceeds from sale of debt securities, available-for-sale for fiscal 2019 was $319.47M.
| Period end | Proceeds from Sale of Debt Securities, Available-for-sale 12 month |
|---|---|
| 2021-12-31 | $1.07B 10-K · filed 2022-02-28 |
| 2020-12-31 | $307.87M 10-K · filed 2022-02-28 |
| 2019-12-31 | $319.47M 10-K · filed 2022-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |